Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 185

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 4
Chunk 185
---
 patent applications we exclusively license. We vigorously defend our intellectual property to preserve our rights and gain the benefit of our investment.

•                      The motixafortide drug product composition of matter and methods of manufacturing thereof are covered by                   
       a granted U.S. patent and patent applications pending in the USA (two applications received notice of allowance). Israel, Europe, Japan,   
      Canada, Australia, China, India, Mexico, Brazil, Hong-Kong and Korea. The patents, if granted, will expire in December 2041, not including  
      any applicable patent term extension, which may add an additional term of up to five years for the U.S. patents. We also have an exclusive  
       license to a patent family that covers motixafortide combined with a PD1 antagonist for the treatment of cancer. Patents of this family    
    have been granted in the U.S., Israel, Australia, China, India, Mexico and Hong Kong; and member patent applications are pending in Australia,
       Hong Kong, Europe, China, Canada, India, Israel and Brazil. The granted U.S. patent and patents to issue in the future based on pending    
    patent applications in this family will expire in 2036, not including any applicable patent term extension. In addition, we have an exclusive 
       license to nineteen other patent families pending or granted worldwide directed to methods of synthesis of motixafortide and methods of    
       use of motixafortide either alone or in combination with other drugs for the treatment of certain types of cancer and other indications.   
        Furthermore, we have Orphan Drug status for AML, pancreatic cancer and stem cell mobilization, as well as data exclusivity protection     
                                                         afforded to motixafortide as an NCE.                                                     
--------------------------------------------------------------------------------------------------------------------------------------------------

•                                With respect to BL-5010, we have an exclusive license to a patent family directed                              
       to a novel applicator uniquely configured for applying the BL-5010 composition to targeted skin tissue safely and effectively. Patents   
    in this family have been granted in the U.S., Europe, Israel, Japan, China, Australia and New Zealand. The patents will expire in 2033-2034.
------------------------------------------------------------------------------------------------------------------------------------------------
 
The patent positions of companies like ours are generally uncertain and involve complex legal and factual questions. Our ability to maintain and solidify our proprietary position for our technology will depend on our success in obtaining effective claims and enforcing those claims once granted. We do not know whether any of our patent applications or those patent